TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2885637
Drug: Tamoxifen for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen for the treatment of first relapse (Control)
Study: 26386578
Drug: Intravenous MDCO-157
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous MDCO-157 75 mg
Study: 26386578
Drug: Intravenous MDCO-157
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous MDCO-157 150 mg
Study: 26386578
Drug: Intravenous MDCO-157
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous MDCO-157 300 mg
Study: 26386578
Drug: Oral Clopidogrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Clopidogrel 300 mg
Study: 20738314
Drug: Physiological sex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiological sex steroid replacement (pSSR) - transdermal oestradiol 100 μg daily for week 1, 150 μg for weeks 2-4; vaginal progesterone 200 mg twice daily for weeks 3-4
Study: 20738314
Drug: Standard hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard hormone replacement treatment (sHRT) - oral ethinyloestradiol 30 μg and 1.5 mg norethisterone daily for weeks 1-3, week 4 'pill-free'
Study: 20738314
Drug: Standard hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard hormone replacement treatment (sHRT)
Study: 2876508
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of SMS 201-995 at doses of 25, 50, 100, and 200 micrograms
Study: 2876508
Drug: Subcutaneous administration
Normalized name: subcutaneous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous administration of SMS 201-995 at doses of 50, 100, 200, and 400 micrograms
Study: 2876508
Drug: Both intravenous
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both intravenous and subcutaneous administration of SMS 201-995
Study: 27267109
Drug: Physiotherapy informed
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Physiotherapy informed by Acceptance and Commitment Therapy (PACT)
Study: 9508225
Drug: IV therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV therapy team
Study: 14608565
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (Control)
Study: 31541635
Drug: 3.6-mL 2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.6-mL 2% lidocaine intracervical block
Study: 31541635
Drug: Sham injection
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham injection (intracervical dry-needling)
Study: 28370160
Drug: Ultrasound-guided core
Normalized name: diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ultrasound-guided core needle biopsy (CNB) in patients undergoing antiplatelet/anticoagulation therapy
Study: 28370160
Drug: Ultrasound-guided core
Normalized name: diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ultrasound-guided core needle biopsy (CNB) in patients not undergoing antiplatelet/anticoagulation therapy
Study: 25481918
Drug: 21-mg nicotine
Normalized name: nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 21-mg nicotine patch
Study: 11106218
Drug: 15-mg nicotine
Normalized name: nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 15-mg nicotine patch
Study: 21364138
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide gas
Study: 26431718
Drug: Inhaled nitrogen
Normalized name: nitrogen Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitrogen placebo
Study: 22665104
Drug: Early invitation
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early invitation with MMS (multiple micronutrients including 30 mg of iron and 400 μg of folic acid)
Study: 22665104
Drug: Usual invitation
Normalized name: BERGAMOT,IMITATION
DrugBank: Bergamot oil (DB14335)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual invitation with 60 mg of iron and 400 μg of folic acid
Study: 8544154
Drug: Iso-osmotic bowel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iso-osmotic bowel preparation (Klean Prep)
Study: 24662398
Drug: evolocumab 140
Normalized name: evolocumab 140 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: evolocumab 140 mg Q2 W
Study: 24662398
Drug: evolocumab 420
Normalized name: evolocumab 420 in 3.5 ML Cartridge
Approvals — FDA: no, EMA: no, PMDA: no
Description: evolocumab 420 mg QM
Study: 23381198
Drug: Methylprednisolone (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (1000 mg intravenously during anesthesia induction)
Study: 17130328
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no steroid administration)
Study: 2958234
Drug: Silicone spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silicone spray
Study: 12952498
Drug: Tetracycline 250
Normalized name: tetracycline 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetracycline 250 mg with centchroman 30 mg
Study: 12952498
Drug: Tetracycline 250
Normalized name: tetracycline 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetracycline 250 mg, centchroman 30 mg, and lactic acid bacillus spores (60 million)
Study: 10647760
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment with nitrendipine (10-40 mg/d), possibly with captopril (12.5-50 mg/d) and/or hydrochlorothiazide (12.5-50 mg/d)
Study: 24863570
Drug: targeted ultraviolet
Approvals — FDA: no, EMA: no, PMDA: no
Description: targeted ultraviolet B (tUVB) treatment
Study: 16091074
Drug: Overall (Morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall (Morphine vs Pethidine)
Study: 9707384
Drug: Levomethadyl acetate
Normalized name: Levomethadyl acetate
DrugBank: Levacetylmethadol (DB01227)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levomethadyl acetate (LAAM) high-dose (100 mg) induction lasting 17 days
Study: 9707384
Drug: Levomethadyl acetate
Normalized name: Levomethadyl acetate
DrugBank: Levacetylmethadol (DB01227)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levomethadyl acetate (LAAM) low-dose (25 mg) induction
Study: 9707384
Drug: Levomethadyl acetate
Normalized name: Levomethadyl acetate
DrugBank: Levacetylmethadol (DB01227)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levomethadyl acetate (LAAM) medium-dose (50 mg) induction lasting 7 days
Study: 7713467
Drug: Enzyme combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzyme combination preparation
Study: 761334
Drug: Reorganized treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reorganized treatment group
Study: 16408442
Drug: Ordinary treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ordinary treatment group
Study: 23406077
Drug: 50/50 nitrous
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50/50 nitrous oxide and oxygen at 9 L/min (N(2) O group)
Study: 23406077
Drug: Medical air
Normalized name: Medical air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical air at 9 L/min (MA group)
Study: 21224456
Drug: Behavioral therapy
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral therapy (pelvic floor muscle training and bladder control strategies)
Study: 21224456
Drug: Behavioral therapy
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral therapy plus biofeedback and pelvic floor electrical stimulation
Study: 15520341
Drug: ATHENA program
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATHENA program (8 weekly 45-minute sessions)
Study: 9607373
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg mibefradil
Study: 9607373
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg mibefradil
Study: 9234827
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg mibefradil
Study: 9234827
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg mibefradil
Study: 1451721
Drug: Clomipramine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomipramine treatment
Study: 3596358
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg of aspirin
Study: 334185
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg of aspirin
Study: 28953493
Drug: Zinc lozenges
Normalized name: Zinc Lozenges
DrugBank: Zinc gluconate (DB11248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zinc lozenges (40 mg) administered 30 minutes preoperatively
Study: 23190837
Drug: Oral rivaroxaban
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral rivaroxaban (10 mg) once daily for 10 days, starting 6 to 8 hours after surgery
Study: 23190837
Drug: Oral placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo once daily for 10 days, starting 6 to 8 hours after surgery
Study: 20160653
Drug: High-dose vitamins
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vitamins (2 g vitamin C and 800 IU vitamin E)
Study: 20160653
Drug: Methionine loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methionine loading (100 mg/kg body weight)
Study: 14622687
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg etoricoxib
Study: 10742934
Drug: 9-month, manual-based,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9-month, manual-based, psychoeducational family therapy
Study: 10742934
Drug: Independent observers'
Approvals — FDA: no, EMA: no, PMDA: no
Description: Independent observers' ratings of overall treatment difficulty
Study: 9003103
Drug: Anticardiolipin antibodies
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticardiolipin antibodies (IgG or IgM)
Study: 9003103
Drug: Anticardiolipin antibodies
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticardiolipin antibodies (IgA)
Study: 1728527
Drug: 5-ASA (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-ASA (2 g/day)
Study: 6093236
Drug: Low secretory
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low secretory IgA concentrations in IM patients, mean value 0.180 g/l
Study: 2942457
Drug: 0.3% foscarnet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3% foscarnet cream for men
Study: 2942457
Drug: 1% foscarnet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% foscarnet cream for women
Study: 2942457
Drug: foscarnet cream
DrugBank: Foscarnet (DB00529)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: foscarnet cream (both dosages)
Study: 22275463
Drug: Virtual reality
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual reality therapy
Study: 16929448
Drug: Preoperative epoetin-alpha
Normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative epoetin-alpha treatment added to standard care
Study: 11756667
Drug: scopolamine (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: scopolamine (0.4 mg)
Study: 9789200
Drug: Melimmune-1 and
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Melimmune-1 and Melimmune-2 administered with SAF-m adjuvant
Study: 2703174
Drug: Intracavitary irradiation
Normalized name: carmustine
DrugBank: Carmustine (DB00262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracavitary irradiation using high dose-rate afterloading technique with 60Co sources
Study: 2703174
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (hysterectomy and radiotherapy)
Study: 342631
Drug: monovalent (A/New
Approvals — FDA: no, EMA: no, PMDA: no
Description: monovalent (A/New Jersey/76) vaccine, single dose
Study: 342631
Drug: split-product vaccines,
Approvals — FDA: no, EMA: no, PMDA: no
Description: split-product vaccines, two-dose regimen
Study: 342631
Drug: bivalent (A/New
Approvals — FDA: no, EMA: no, PMDA: no
Description: bivalent (A/New Jersey/76-A/Victoria/75) vaccines, high doses of split-product
Study: 342631
Drug: whole-virus vaccines
Normalized name: Rubella virus vaccine
DrugBank: Rubella virus vaccine (DB10317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: whole-virus vaccines
Study: 30358156
Drug: L-arginine (17.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (17.1 mmol)
Study: 23240499
Drug: Influenza vaccine
Normalized name: Influenza vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Influenza vaccine subunit strain A/California/7/2009/(H1N1)v
Study: 18418962
Drug: Oxymatrine plus
Normalized name: Oxymatrine
DrugBank: Oxymatrine (DB16276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxymatrine plus Western routine therapy
Study: 18418962
Drug: Western routine
Normalized name: western larch pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western routine therapy (Control)
Study: 12844131
Drug: Standard oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard oral dexamethasone regimen (20 mg on day 1, 8 mg on days 2 to 5) plus ondansetron (32 mg IV on day 1)
Study: 12844131
Drug: Modified dexamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified dexamethasone regimen (12 mg on day 1, 4 mg on days 2 to 5) plus ondansetron (32 mg IV on day 1)
Study: 12844131
Drug: Methylprednisolone regimen
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone regimen (125 mg IV on day 1, 40 mg orally on days 2 to 3) with aprepitant (125 mg on day 1, 80 mg on days 2 to 3)
Study: 10325897
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (FP), 500 micrograms twice daily
Study: 10325897
Drug: Budesonide (BUD),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (BUD), 800 micrograms twice daily
Study: 8612314
Drug: Ftorafur (FT)
DrugBank: Tegafur-uracil (DB09327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ftorafur (FT) 600 mg/day
Study: 8612314
Drug: Ftorafur (FT)
DrugBank: Tegafur-uracil (DB09327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ftorafur (FT) 600 mg/day plus Tamoxifen (TAM) 20 mg/day
Study: 1787937
Drug: Topical prednisolone
Normalized name: prednisolone Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical prednisolone 1%
Study: 31429150
Drug: Fractional excretion
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractional excretion of UA
Study: 12366503
Drug: Fluid administration
Normalized name: Fluid Administration Set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluid administration <1 litre
Study: 12366503
Drug: Fluid administration
Normalized name: Fluid Administration Set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluid administration ≥1 litre
Study: 12366503
Drug: No fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No fluid administration (Control)
Study: 11041318
Drug: Zolmitriptan (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolmitriptan (5 mg per os)
Study: 2055827
Drug: High-carbohydrate diet
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-carbohydrate diet (10 g.kg body mass‐1.day‐1)
Study: 2055827
Drug: Moderate-carbohydrate diet
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate-carbohydrate diet (5 g.kg body mass‐1.day‐1)
Study: 7081096
Drug: 100 mg/day
Normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/day zinc supplementation
Study: 7081096
Drug: 15 mg/day
Normalized name: Climara Pro 0.045/0.015 MG/Day Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/day zinc supplementation
Study: 7081096
Drug: 50 mg/day
Normalized name: infigratinib phosphate 50 mg/day (25 mg x 2) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg/day zinc supplementation
Study: 7081096
Drug: 0 mg/day
Normalized name: RibaTab 800 mg/day Compliance Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg/day zinc supplementation (placebo)
Study: 1095310
Drug: Nystatin therapy
Normalized name: Nystatin
DrugBank: Nystatin (DB00646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nystatin therapy
Study: 28631901
Drug: Perforated ultra‐lightweight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perforated ultra‐lightweight polypropylene implant (surface density 19 g/m2)
Study: 28631901
Drug: Lightweight polypropylene
Normalized name: polypropylene (30000 MW)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lightweight polypropylene implant (surface density 42.7 g/m2)
Study: 21205556
Drug: Zinc in
Normalized name: Zinc insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc in tablet form
Study: 21205556
Drug: Zinc in
Normalized name: Zinc insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc in suspension form
Study: 21205556
Drug: WHO recommended
Normalized name: ALCOHOL 80 mL in 100 mL TOPICAL LIQUID [WHO Recommended Hand Rub]
Approvals — FDA: no, EMA: no, PMDA: no
Description: WHO recommended treatment for diarrhoea
Study: 17395055
Drug: Cardiac contractility
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac contractility modulation (CCM) therapy; delivered continuously for 30 minutes in patients and 2 hours in dogs
Study: 16128874
Drug: Advice to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Advice to drink 1.5 l of water per day
Study: 11870165
Drug: Paclitaxel 175
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 175 mg/m² IV every 21 days
Study: 11870165
Drug: Cyclophosphamide 500
Normalized name: cyclophosphamide 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide 500 mg/m², Doxorubicin 50 mg/m², and Cisplatin 50 mg/m² (CAP) IV every 21 days
Study: 10197659
Drug: Pump prime
Normalized name: DELTYL PRIME
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pump prime only aprotinin (280 mg)
Study: 3476058
Drug: Enteric coated
Normalized name: Mesasal Enteric Coated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric coated aspirin 20 mg daily
Study: 3476058
Drug: Enteric coated
Normalized name: Mesasal Enteric Coated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric coated aspirin 40 mg daily
Study: 3476058
Drug: Enteric coated
Normalized name: Mesasal Enteric Coated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric coated aspirin 60 mg daily
Study: 3476058
Drug: Enteric coated
Normalized name: Mesasal Enteric Coated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric coated aspirin 60-80 mg daily
Study: 3476058
Drug: Enteric coated
Normalized name: Mesasal Enteric Coated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric coated aspirin greater than 100 mg daily
Study: 3476058
Drug: Enteric coated
Normalized name: Mesasal Enteric Coated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric coated aspirin 80 mg daily
Study: 3476058
Drug: Enteric coated
Normalized name: Mesasal Enteric Coated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric coated aspirin 100 mg daily
Study: 22913409
Drug: Heat patch
Normalized name: CVS Body Heat Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heat patch containing iron chip
Study: 15859526
Drug: Sham short-wave
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham short-wave diathermy treatment (control)
Study: 11801587
Drug: Liposomal amphotericin
Normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liposomal amphotericin B 3 mg/kg/day
Study: 11801587
Drug: Liposomal amphotericin
Normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liposomal amphotericin B 5 mg/kg/day
Study: 11801587
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B lipid complex (ABLC) 5 mg/kg/day
Study: 10401542
Drug: Eight week
Normalized name: OC Eight
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eight week rehabilitation programme combining group and individual therapies
Study: 8904255
Drug: Epidural sufentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural sufentanil (50 mu g in 10 ml normal saline)
Study: 8904255
Drug: Control (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (10 ml normal saline)
Study: 8904255
Drug: Epidural sufentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural sufentanil (50 mu g in 50 ml bupivacaine 0.125% at a rate of 6-10 ml/h)
Study: 1919423
Drug: Non-pharmacological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-pharmacological treatment (NPT) programme
Study: 31471246
Drug: Blonanserin 40
Normalized name: Blonanserin
DrugBank: Blonanserin (DB09223)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Blonanserin 40 mg
Study: 31471246
Drug: Blonanserin 80
Normalized name: Blonanserin
DrugBank: Blonanserin (DB09223)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Blonanserin 80 mg
Study: 30115212
Drug: Willingness to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Willingness to prescribe antidepressants
Study: 26273146
Drug: I-gel facilitated
Normalized name: iobenguane I-131
Approvals — FDA: no, EMA: no, PMDA: no
Description: I-gel facilitated endotracheal tube intubation (Group TI)
Study: 22525775
Drug: Combined Treatment
Normalized name: POISON IVY/OAK/SUMAC EXTRACTS COMBINED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined Treatment (AT/RT)
Study: 19788364
Drug: Vaginal estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal estrogen therapy (creams, tablets, rings)
Study: 17971946
Drug: BCG-PSN injection
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG-PSN injection plus inhaled glucocortisteriods
Study: 17971946
Drug: Inhaled glucocortisteriods
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled glucocortisteriods only
Study: 10548622
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml of 1.5% lignocaine (group A)
Study: 10548622
Drug: No local
Approvals — FDA: no, EMA: no, PMDA: no
Description: No local injection (group C)
Study: 31607677
Drug: Simvastatin 40
Normalized name: simvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 40 mg/day plus rifaximin 1200 mg/day